NCT07927400
An Exploratory Study of the Efficacy and Safety of SBRT Following Induction Therapy With Neoadjuvant Immunotherapy Combined With Chemotherapy in Muscle-Invasive Bladder Cancer
StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Clinical complete remission (cCR)
Timeframe: 3year
Bladder event-free survival (BI-EFS)
Timeframe: 3year
Secondary (5)
Relapse-free survival (RFS)
cancer-specific survival (CSS)
disease-free survival (DFS)
overall survival (OS)
bladder preservation rate
Arms and interventions
Experimental groupExperimental
Maximal TURBT; Induction therapy: Suliimab combined with gemcitabine and cisplatin/oral carboplatin, for a total of 2 cycles; Concurrent chemoradiotherapy (after completing 2 cycles of induction therapy); One course of SBRT radiotherapy: 25Gy/5Gy/5f for the tumor area/tumor bed of the primary bladder lesion; Two courses of external beam radiotherapy: Bladder radiotherapy (45Gy/1.8Gy/25F); Cystoscopy TURBT; Maintenance therapy.
Drugs: Suruilimab immunotherapy